دورية أكاديمية
أعرض في EDS

Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer.

التفاصيل البيبلوغرافية
العنوان: Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer.
المؤلفون: Cheng CL; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong.; Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong., Tsang FH; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong.; Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong., Wei L; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong.; Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong., Chen M; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong.; Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong., Chin DW; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong.; Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong., Shen J; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong.; Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong., Law CT; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong.; Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong., Lee D; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong.; Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong., Wong CC; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong.; Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong., Ng IO; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong.; Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong., Wong CM; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong. jackwong@pathology.hku.hk.; Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong. jackwong@pathology.hku.hk.
المصدر: Communications biology [Commun Biol] 2021 Jul 20; Vol. 4 (1), pp. 888. Date of Electronic Publication: 2021 Jul 20.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group UK Country of Publication: England NLM ID: 101719179 Publication Model: Electronic Cited Medium: Internet ISSN: 2399-3642 (Electronic) Linking ISSN: 23993642 NLM ISO Abbreviation: Commun Biol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London, United Kingdom : Nature Publishing Group UK, [2018]-
مواضيع طبية MeSH: Transcriptional Activation*, Adaptor Proteins, Signal Transducing/*genetics , Carcinoma, Hepatocellular/*drug therapy , DNA-Binding Proteins/*genetics , Liver Neoplasms/*drug therapy, Adaptor Proteins, Signal Transducing/metabolism ; Animals ; Carcinoma, Hepatocellular/genetics ; DNA-Binding Proteins/metabolism ; Humans ; Liver Neoplasms/genetics ; Male ; Mice ; Mice, Inbred BALB C
مستخلص: Epigenetic deregulation plays an essential role in hepatocellular carcinoma (HCC) progression. Bromodomains are epigenetic "readers" of histone acetylation. Recently, bromodomain inhibitors have exhibited promising therapeutic potential for cancer treatment. Using transcriptome sequencing, we identified BRPF1 (bromodomain and PHD finger containing 1) as the most significantly upregulated gene among the 43 bromodomain-containing genes in human HCC. BRPF1 upregulation was significantly associated with poor patient survival. Gene ablation or pharmacological inactivation of BRPF1 significantly attenuated HCC cell growth in vitro and in vivo. BRPF1 was involved in cell cycle progression, senescence and cancer stemness. Transcriptome sequencing revealed that BRPF1 is a master regulator controlling the expression of multiple key oncogenes, including E2F2 and EZH2. We demonstrated that BRPF1 activated E2F2 and EZH2 expression by facilitating promoter H3K14 acetylation through MOZ/MORF complex. In conclusion, BRPF1 is frequently upregulated in human HCCs. Targeting BRPF1 may be an approach for HCC treatment.
(© 2021. The Author(s).)
References: Nat Commun. 2018 Dec 3;9(1):5139. (PMID: 30510198)
Leukemia. 2005 Dec;19(12):2344-5. (PMID: 16193081)
Gut. 2021 Jan;70(1):157-169. (PMID: 32217639)
Cell Stem Cell. 2019 Jan 3;24(1):25-40. (PMID: 30595497)
Hepatology. 2019 May;69(5):2013-2030. (PMID: 30516846)
Nat Rev Drug Discov. 2006 Jan;5(1):37-50. (PMID: 16485345)
FEBS J. 2015 Jan;282(2):224-58. (PMID: 25393971)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Mol Cell. 2001 Jul;8(1):105-13. (PMID: 11511364)
Biochim Biophys Acta. 2015 Aug;1853(8):1818-26. (PMID: 25920810)
N Engl J Med. 2008 Jul 24;359(4):378-90. (PMID: 18650514)
Cell. 2011 Sep 16;146(6):904-17. (PMID: 21889194)
J Gastrointest Cancer. 2017 Sep;48(3):238-240. (PMID: 28626852)
J Hepatocell Carcinoma. 2019 Jan 31;6:31-39. (PMID: 30775342)
Oncogene. 2016 Sep 8;35(36):4689-97. (PMID: 26804177)
Clin Mol Hepatol. 2016 Sep;22(3):309-318. (PMID: 27729631)
Genes Chromosomes Cancer. 2000 Jun;28(2):138-44. (PMID: 10824998)
Sci Adv. 2020 Jan 22;6(4):eaax0021. (PMID: 32010779)
Hepatology. 2019 Jun;69(6):2502-2517. (PMID: 30723918)
Clin Liver Dis. 2015 May;19(2):223-38. (PMID: 25921660)
Biochem J. 2007 Mar 15;402(3):559-66. (PMID: 17083329)
Am J Hum Genet. 2017 Jan 5;100(1):91-104. (PMID: 27939640)
Oncologist. 2009 Jan;14(1):95-100. (PMID: 19144678)
Br J Cancer. 2014 Mar 4;110(5):1189-98. (PMID: 24518598)
Oncogene. 2002 Apr 18;21(17):2729-40. (PMID: 11965546)
Oncotarget. 2016 Jan 19;7(3):2462-74. (PMID: 26575167)
Hepatology. 2013 Feb;57(2):637-47. (PMID: 22991213)
Cell. 2006 Apr 21;125(2):301-13. (PMID: 16630818)
Nat Genet. 2014 Dec;46(12):1267-73. (PMID: 25362482)
Cancer. 2006 Apr 15;106(8):1794-803. (PMID: 16532500)
Cancer Cell. 2014 Mar 17;25(3):393-405. (PMID: 24651015)
Nat Rev Mol Cell Biol. 2015 Apr;16(4):258-64. (PMID: 25549891)
Nat Commun. 2019 Oct 17;10(1):4724. (PMID: 31624313)
J Clin Oncol. 2018 Oct 20;36(30):3007-3014. (PMID: 29733771)
Dev Cell. 2009 Nov;17(5):674-86. (PMID: 19922872)
Int J Mol Sci. 2016 Nov 07;17(11):. (PMID: 27827996)
N Engl J Med. 2018 Jul 05;379(1):54-63. (PMID: 29972759)
Mol Cell Biol. 2008 Nov;28(22):6828-43. (PMID: 18794358)
J Hepatol. 2017 Aug;67(2):302-309. (PMID: 28336466)
Hepatology. 2016 Feb;63(2):474-87. (PMID: 26481868)
ACS Chem Biol. 2017 Oct 20;12(10):2619-2630. (PMID: 28849908)
Clin Cancer Res. 2019 Nov 1;25(21):6309-6319. (PMID: 31420359)
Genes Dev. 2012 Jun 15;26(12):1376-91. (PMID: 22713874)
Nature. 2010 Dec 23;468(7327):1067-73. (PMID: 20871596)
Lancet. 2017 Jan 7;389(10064):56-66. (PMID: 27932229)
Science. 2017 Jul 21;357(6348):. (PMID: 28729483)
Oncotarget. 2015 Oct 20;6(32):33623-35. (PMID: 26378038)
Cell Rep. 2017 Feb 28;18(9):2162-2174. (PMID: 28249162)
Bioinformatics. 2012 Aug 15;28(16):2205-6. (PMID: 22718786)
Hepatology. 2012 Aug;56(2):622-31. (PMID: 22370893)
Mol Cell. 2016 Apr 21;62(2):169-180. (PMID: 27105113)
J Clin Invest. 2016 Sep 1;126(9):3247-62. (PMID: 27500495)
Int J Hematol. 2014 Jan;99(1):21-31. (PMID: 24258712)
World J Hepatol. 2013 Jul 27;5(7):345-52. (PMID: 23898367)
Lancet Haematol. 2016 Apr;3(4):e186-95. (PMID: 27063977)
Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8758-63. (PMID: 12840145)
Semin Liver Dis. 1999;19(3):311-22. (PMID: 10518310)
J Hepatol. 2017 Oct;67(4):758-769. (PMID: 28532996)
J Biol Chem. 2015 Mar 13;290(11):7114-29. (PMID: 25568313)
Cell Rep. 2019 Dec 17;29(12):4036-4052.e10. (PMID: 31851932)
Epigenetics. 2014 Feb;9(2):186-93. (PMID: 24169304)
Cancer Res. 2017 Jun 1;77(11):2976-2989. (PMID: 28416490)
Cell Rep. 2016 Sep 13;16(11):2829-2837. (PMID: 27626654)
المشرفين على المادة: 0 (Adaptor Proteins, Signal Transducing)
0 (BRPF1 protein, human)
0 (DNA-Binding Proteins)
تواريخ الأحداث: Date Created: 20210721 Date Completed: 20211111 Latest Revision: 20211111
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8292510
DOI: 10.1038/s42003-021-02405-6
PMID: 34285329
قاعدة البيانات: MEDLINE
الوصف
تدمد:2399-3642
DOI:10.1038/s42003-021-02405-6